• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by Renovacor Inc. (Amendment)

    4/5/23 4:31:54 PM ET
    $RCOR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $RCOR alert in real time by email
    SC 13D/A 1 p23-1137sc13da.htm RENOVACOR, INC.
    SECURITIES AND EXCHANGE COMMISSION  
       
    Washington, D.C. 20549  
    _______________  
       
    SCHEDULE 13D/A
     
    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT
    TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO
    RULE 13d-2(a)
     
    Under the Securities Exchange Act of 1934
    (Amendment No. 1)
     

    Renovacor, Inc.

    (Name of Issuer)
     

    Common Stock, par value $0.0001 per share

    (Title of Class of Securities)
     

    75989E106

    (CUSIP Number)
     

    Eleazer Klein, Esq.

    Adriana Schwartz, Esq.

    919 Third Avenue
    New York, New York 10022

    (212) 756-2000

    (Name, Address and Telephone Number of Person
    Authorized to Receive Notices and Communications)
     

    December 1, 2022

    (Date of Event which Requires
    Filing of this Schedule)

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box. [X]

     

    NOTE: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent.

     

    (Continued on following pages)

    (Page 1 of 5 Pages)

    --------------------------

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    CUSIP No. 75989E106SCHEDULE 13D/APage 2 of 5 Pages

     

    1

    NAME OF REPORTING PERSON

    RTW Investments, LP

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    SOURCE OF FUNDS

    AF

    5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDING IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) ¨
    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    7

    SOLE VOTING POWER

    0

    8

    SHARED VOTING POWER

    0

    9

    SOLE DISPOSITIVE POWER

    0

    10

    SHARED DISPOSITIVE POWER

    0

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH PERSON

    0

    12 CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES ¨
    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) (see Item 5)

    0%

    14

    TYPE OF REPORTING PERSON

    PN, IA

             

     

     

     

    CUSIP No. 75989E106SCHEDULE 13D/APage 3 of 5 Pages

     

    1

    NAME OF REPORTING PERSON

    Roderick Wong

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    SOURCE OF FUNDS

    AF

    5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDING IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) ¨
    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United States

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    7

    SOLE VOTING POWER

    0

    8

    SHARED VOTING POWER

    0

    9

    SOLE DISPOSITIVE POWER

    0

    10

    SHARED DISPOSITIVE POWER

    0

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH PERSON

    0

    12 CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES ¨
    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) (see Item 5)

    0%

    14

    TYPE OF REPORTING PERSON

    IN, HC

             

     

    CUSIP No. 75989E106SCHEDULE 13D/APage 4 of 5 Pages

     

    The following constitutes Amendment No. 1 to the Schedule 13D filed by the undersigned (the “Amendment No. 1”). This Amendment No. 1 amends the Schedule 13D as specifically set forth herein. This Amendment No. 1 is the final amendment to the Schedule 13D and constitutes an "exit filing" for the Reporting Persons.

    Item 4. PURPOSE OF TRANSACTION.
       
    Item 4 of the Schedule 13D is hereby amended to add the following:

     

    The Mergers closed on December 1, 2022. At the closing of the Mergers (the “Closing”), each of the Issuer’s Shares outstanding immediately prior to the effective time of the First Merger (the “First Effective Time”) was canceled and converted into the right to receive 0.1763 fully paid and non-assessable shares of Rocket common stock, $0.01 par value per share (“Rocket Shares”). At the First Effective Time, each public warrant to purchase Issuer Shares (“Renovacor Public Warrant”) outstanding and unexercised immediately prior to the First Effective Time was automatically converted into a number of warrants (the “Rocket Warrants”), rounded down to the nearest whole share, equal to the product of (A) the number of Issuer Shares subject to such Renovacor Public Warrant as of immediately prior to the First Effective Time, multiplied by (B) the Exchange Ratio (as defined in the Merger Agreement, after such conversion, a Rocket Warrant), at an exercise price per Rocket Share underlying such Exchanged Warrant equal to the quotient obtained by dividing (x) the per share exercise price applicable to such Renovacor Public Warrant immediately prior to the First Effective Time by (y) the Exchange Ratio, rounded up to the nearest whole cent. Each Rocket Warrant is exercisable for one-half of a Rocket Share, provided, however, each Rocket Warrant must be exercised in multiples of two. In connection with the Closing of the Mergers, 3,000,803 Shares held by the Reporting Persons were converted into 529,038 Rocket Shares, and warrants exercisable for 350,000 Shares held by the Reporting Persons were converted into 61,705 Rocket Warrants exercisable for 30,852 Rocket Shares. As a result, the Reporting Persons no longer beneficially owned any Shares or warrants of the Issuer.

    The foregoing summary of the transactions that were consummated pursuant to the Merger Agreement does not purport to be complete and is qualified in its entirety by, the full text of the Current Report on Form 8-K filed by the Issuer with the SEC on December 1, 2022, and is incorporated herein by reference.

    Item 5. INTEREST IN SECURITIES OF THE COMPANY.
       
    Item 5(a)-(c), (e) of the Schedule 13D is hereby amended and restated in its entirety as follows:

     

    (a) See rows (11) and (13) of the cover page to this Schedule 13D for the aggregate number of Shares and percentages of the Shares beneficially owned by the Reporting Persons.  

    (b) See rows (7) through (10) of the cover page to this Schedule 13D for the number of Shares as to which each Reporting Person has the sole or shared power to vote or direct the vote and sole or shared power to dispose or to direct the disposition.

    (c) None, other than as described in Item 4.

    (e) December 1, 2022.

     

     

    CUSIP No. 75989E106SCHEDULE 13D/APage 5 of 5 Pages

     

    SIGNATURES

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    DATED:  April 5, 2023  
       
       
    RTW INVESTMENTS, LP  
         
    By: /s/ Roderick Wong, M.D.  
    Name: Roderick Wong, M.D.  
    Title: Managing Partner  
         
         
         
    /s/ Roderick Wong, M.D.  
    RODERICK WONG, M.D.  
         

     

    Get the next $RCOR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $RCOR

    DatePrice TargetRatingAnalyst
    9/13/2022$9.00Outperform
    Robert W. Baird
    10/14/2021$22.00Buy
    Ladenburg Thalmann
    10/1/2021$20.00Buy
    Chardan Capital Markets
    More analyst ratings

    $RCOR
    SEC Filings

    See more
    • SEC Form 15-12G filed by Renovacor Inc.

      15-12G - Renovacor, Inc. (0001799850) (Filer)

      12/12/22 4:35:37 PM ET
      $RCOR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Renovacor Inc.

      EFFECT - Renovacor, Inc. (0001799850) (Filer)

      12/6/22 12:15:05 AM ET
      $RCOR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Renovacor Inc.

      EFFECT - Renovacor, Inc. (0001799850) (Filer)

      12/6/22 12:15:13 AM ET
      $RCOR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RCOR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Rockwell Medical Appoints Joan Lau, Ph.D. to the Company's Board of Directors

      Brings more than 20 years of experience as an entrepreneur scientist, CEO, operator, investor, and board member of public and private biopharmaceutical companies Rockwell Medical, Inc. (the "Company") (NASDAQ:RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that the Company appointed Joan Lau, Ph.D. to its board of directors. Dr. Lau's appointment increases Rockwell Medical's board of directors to seven members. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231017906241/en/RMTI) (Photo: Business Wire)"

      10/17/23 6:00:00 AM ET
      $BDN
      $RMTI
      $RCOR
      Real Estate Investment Trusts
      Real Estate
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rocket Pharmaceuticals Completes Acquisition of Renovacor

      Acquisition further extends Rocket's leadership in AAV-based cardiac gene therapy and expands focus and capabilities to BAG3-associated dilated cardiomyopathy Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT), a leading late-stage biotechnology company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders with high unmet need, today announces that it has completed the previously announced acquisition of Renovacor, Inc. (NYSE:RCOR), a biotechnology company focused on delivering innovative precision therapies to improve the lives of patients and families battling genetically-driven cardiovascular and mechanistically-related diseases. Under the terms of t

      12/1/22 4:01:00 PM ET
      $RCKT
      $RCOR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rocket Pharmaceuticals to Acquire Renovacor, Extending Leadership in AAV-based Cardiac Gene Therapy

      Acquisition further strengthens Rocket's leadership in AAV-based cardiac gene therapy and expands Company's near-term clinical assets for the treatment of heart conditions Significant unmet medical need in BAG3-associated dilated cardiomyopathy, with meaningful commercial opportunity, comparable to Danon Disease Creates strong synergies by combining key assets, personnel, capabilities and IP, as well as access to world-leading scientific and clinical collaborators, expected to deliver long-term value for Rocket and Renovacor shareholders We believe compelling preclinical data generated by Renovacor validates mechanism of action of AAV-based transgene replacement strategy for BAG-3 di

      9/20/22 6:00:00 AM ET
      $RCKT
      $RCOR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RCOR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by Renovacor Inc. (Amendment)

      SC 13D/A - Renovacor, Inc. (0001799850) (Subject)

      4/5/23 4:31:54 PM ET
      $RCOR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Renovacor Inc. (Amendment)

      SC 13G/A - Renovacor, Inc. (0001799850) (Subject)

      2/14/23 7:41:31 AM ET
      $RCOR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D filed by Renovacor Inc.

      SC 13D - Renovacor, Inc. (0001799850) (Subject)

      9/21/22 9:00:09 AM ET
      $RCOR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RCOR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Rtw Investments, Lp

      4 - Renovacor, Inc. (0001799850) (Issuer)

      4/5/23 4:30:43 PM ET
      $RCOR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Needham Thomas E. Jr.

      4 - Renovacor, Inc. (0001799850) (Issuer)

      12/5/22 9:24:00 PM ET
      $RCOR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Lau Joan

      4 - Renovacor, Inc. (0001799850) (Issuer)

      12/5/22 9:23:45 PM ET
      $RCOR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RCOR
    Leadership Updates

    Live Leadership Updates

    See more

    $RCOR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Rockwell Medical Appoints Joan Lau, Ph.D. to the Company's Board of Directors

      Brings more than 20 years of experience as an entrepreneur scientist, CEO, operator, investor, and board member of public and private biopharmaceutical companies Rockwell Medical, Inc. (the "Company") (NASDAQ:RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that the Company appointed Joan Lau, Ph.D. to its board of directors. Dr. Lau's appointment increases Rockwell Medical's board of directors to seven members. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231017906241/en/RMTI) (Photo: Business Wire)"

      10/17/23 6:00:00 AM ET
      $BDN
      $RMTI
      $RCOR
      Real Estate Investment Trusts
      Real Estate
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Renovacor Announces the Appointment of Kumar Dhanasekharan, Ph.D., as Senior Vice President of Technical Operations

      Dr. Dhanasekharan joins Renovacor with extensive experience overseeing development, manufacturing and supply operations for biologics including AAV gene therapies Renovacor, Inc. (NYSE:RCOR), a biotechnology company developing adeno-associated virus (AAV)‑based gene therapies for devastating cardiovascular and central nervous system diseases resulting from BAG3 gene variants, today announced the appointment of Kumar Dhanasekharan, Ph.D., as Senior Vice President of Technical Operations. "With Kumar's appointment, we've added yet another innovative industry expert to Renovacor's diverse and growing leadership team," said Magdalene Cook, M.D., Chief Executive Officer of Renovacor. "Kumar is

      10/4/21 4:05:00 PM ET
      $RCOR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Renovacor Announces the Appointment of Jordan Shin, M.D., Ph.D., as Senior Vice President of Clinical Development and Translational Science

      Dr. Shin to help advance REN-001 into the clinic by leveraging nearly two decades of expertise in clinical development, academic research and medical practice Renovacor, Inc. (NYSE:RCOR), an early-stage biotechnology company developing adeno-associated virus (AAV)-based gene therapies for devastating cardiovascular and central nervous system diseases resulting from BAG3 gene variants, today announced the appointment of Jordan Shin, M.D., Ph.D., as Senior Vice President of Clinical Development and Translational Science. "We are excited to welcome Jordan to Renovacor's leadership team during this pivotal time for the company," said Magdalene Cook, M.D., Chief Executive Officer of Renovacor.

      9/22/21 4:05:00 PM ET
      $RCOR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Robert W. Baird initiated coverage on Renovacor with a new price target

      Robert W. Baird initiated coverage of Renovacor with a rating of Outperform and set a new price target of $9.00

      9/13/22 7:37:19 AM ET
      $RCOR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ladenburg Thalmann initiated coverage on Renovacor with a new price target

      Ladenburg Thalmann initiated coverage of Renovacor with a rating of Buy and set a new price target of $22.00

      10/14/21 7:14:33 AM ET
      $RCOR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chardan Capital Markets initiated coverage on Renovacor with a new price target

      Chardan Capital Markets initiated coverage of Renovacor with a rating of Buy and set a new price target of $20.00

      10/1/21 7:39:25 AM ET
      $RCOR
      Biotechnology: Pharmaceutical Preparations
      Health Care